Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.
NCT00404989
Recruiting
The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is provided to the Registry prospectively (prior to the outcome of pregnancy being known) through their health care provider, with fo... Read More
Gender:
Female
Ages:
Between 12 years and 60 years
Trial Updated:
11/20/2023
Locations: Registry Coordinating Center, Wilmington, North Carolina
Conditions: HIV Infections, Hepatitis B
Register for Updates
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
NCT03692897
Recruiting
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Banner University Medical Center Phoenix, Phoenix, Arizona +30 locations
Conditions: Hepatitis B, Hepatitis, Liver Diseases
Register for Updates
Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure)
NCT04954859
Recruiting
This is a long-term follow-up study to assess durability of efficacy, as measured by SVR, in participants who have received prior treatment with GSK3228836 and achieved a complete or partial response. No further treatment with GSK3228836 will be administered in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: GSK Investigational Site, Sacramento, California +71 locations
Conditions: Hepatitis B
Register for Updates
Evaluation of Patients With Liver Disease
NCT00001971
Recruiting
The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver. Patients participating in the study will first undergo a routine check-up as an outpatient. They will be asked to provide blood and urine samples for laboratory testing and will undergo an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and texture of the liver. After th... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
11/04/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Liver Disease, Hepatitis D, Hepatitis C, Hepatitis B
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Arizona Health Research, Chandler, Arizona +36 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
NCT05404919
Recruiting
The objective of this study is to determine the safety and efficacy of transplanting lungs from hepatitis B virus (HBV) nucleic acid test positive (NAT+) donors into HBV vaccinated HBV surface antibody positive (sAb+) lung transplant candidates, who will then be treated with Hepatitis B Immune Globulin (HBIG) and entecavir, tenofovir disoproxil, or tenofovir alafenamide.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/02/2023
Locations: Hospital of University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Transplant, Hepatitis B
Register for Updates
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
NCT05551273
Recruiting
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
07/21/2023
Locations: Alabama CRS, Birmingham, Alabama +37 locations
Conditions: Hepatitis B, HIV Infections
Register for Updates
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
NCT05181826
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/10/2023
Locations: Torrance Memorial Physician Network - Cancer Care, Redondo Beach, California +6 locations
Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Register for Updates
Blood Collection Biorepository for Liver Disease Research
NCT03025074
Recruiting
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.
Gender:
All
Ages:
7 years and above
Trial Updated:
05/02/2023
Locations: University at Buffalo, Buffalo General Medical Center, Buffalo, New York
Conditions: Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Register for Updates
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
NCT03534141
Recruiting
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies). Patients who experience AKI after liver transplantation have higher mortality, increased graft loss, longer hospital and intensive care unit stays, and more progression to chronic kidney disease compared with those who do not. In this study, half of the participants will have their body temperature cooled to slightly lower than normal (mild hypothermia) for... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/20/2023
Locations: University of California, San Francisco, San Francisco, California +2 locations
Conditions: Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Register for Updates
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
NCT05272735
Recruiting
Antibodies are the primary mediators of the protection against infection provided by vaccination. Antibodies become most powerful after the B cells that produce them undergo an evolutionary process called affinity maturation, in which antibodies increase their ability to bind to their targets, and thus neutralize pathogens. Affinity maturation occurs in structures within secondary lymphoid organs (for example lymph nodes or tonsils) known as germinal centers. Germinal centers are well known to b... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
01/17/2023
Locations: The Rockefeller University, New York, New York
Conditions: Hepatitis B
Register for Updates
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
NCT04588077
Recruiting
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/24/2022
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Register for Updates